Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c01938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Yunhang Guo und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China. Hauptthemen laut MEDLINE: Autoimmune Diseases, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Bruton's tyrosine kinase (BTK) plays an essential role in B-cell receptor (BCR)-mediated signaling as well as the downstream signaling pathway for Fc receptors (FcRs). Targeting BTK for B-cell malignancies by interfering with BCR signaling has been clinically validated by some covalent inhibitors, but suboptimal kinase selectivity may lead to some adverse effects, which also makes the clinical development of autoimmune disease therapy more challenging. The structure-activity relationship (SAR) starting from zanubrutinib (BGB-3111) leads to a series of highly selective BTK inhibitors, in which BGB-8035 is located in the ATP binding pocket and has similar hinge binding to ATP but exhibits high selectivity over other kinases (EGFR, Tec, etc.). With an excellent pharmacokinetic profile as well as demonstrated efficacy studies in oncology and autoimmune disease models, BGB-8035 has been declared a preclinical candidate. However, BGB-8035 showed an inferior toxicity profile compared to that of BGB-3111.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China.
- Department of In Vivo Pharmacology, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China.
- Department of Molecular Science, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China.
- Department of Discovery Biology, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China.
- Department of DMPK-BA, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China.
- Department of Nonclinical Safety Assessment, BeiGene (Beijing) Co., Ltd., Beijing 102206, P.R. China.
ORCID-Profile: Yunhang Guo, Changyou Zhou, Zhiwei Wang
Zitieren
APA
Guo, Y., Hu, N., Liu, Y., Zhang, W., Yu, D., Shi, G., Zhang, B., Yin, L., Wei, M., Yuan, X., Luo, L., Wang, F., Song, X., Xin, L., Wei, Q., Li, Y., Guo, Y., Chen, S., Zhang, T., …, & Wang, Z. (2023). Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01938
Vancouver
Guo Y, Hu N, Liu Y, Zhang W, Yu D, Shi G, et al. Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01938
BibTeX
@article{Guo2023,
author = {Guo, Yunhang and Hu, Nan and Liu, Ye and Zhang, Wei and Yu, Desheng and Shi, Gongyin and Zhang, Bo and Yin, Longbo and Wei, Min and Yuan, Xi and Luo, Lusong and Wang, Fan and Song, Xiaomin and Xin, Lei and Wei, Qiang and Li, Yong and Guo, Ying and Chen, Shuaishuai and Zhang, Taichang and Zhang, Shuo and Zhou, Xing and Zhang, Cuining and Su, Dan and Liu, Junhua and Cheng, Zhenzhen and Zhang, Jiye and Xing, Haimei and Sun, Hanzi and Li, Xin and Zhao, Yuan and He, Min and Wu, Yue and Guo, Yin and Sun, Xuebing and Tian, Alice and Zhou, Changyou and Young, Steve and Liu, Xuesong and Wang, Lai and Wang, Zhiwei},
title = {Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c01938}
}
EUVIMED